GLP-1 Drug Shortages: Key Challenges & Path Forward
- premierpharmamentors
- 6 days ago
- 1 min read
Despite FDA announcements that semaglutide and tirzepatide shortages have resolved, patients and providers still face real-world access barriers. Our latest analysis, authored by Mayur Krishna and Saman Siddique, dives into why functional shortages persist—and what strategies can help stabilize access.
Key insights:
Manufacturing output has expanded, but dose-strength mismatches and distribution bottlenecks continue to disrupt care.
Insurance coverage gaps leave some patients paying >$1,000/month, forcing discontinuation and risking clinical backsliding.
The compounding shutdown created affordability challenges, highlighting the urgency for policy innovation and oral GLP-1 R&D.
Long-term solutions include expanding global capacity, adopting value-based contracts, and prioritizing high-need patients with transparent criteria
.
At Premier Pharma Mentors, we believe bridging the gap between policy, access, and innovation will be key to ensuring sustainable availability of these life-changing therapies.
📊 Listen to the full presentation to see our framework for navigating GLP-1 shortages and building resilient market access strategies.
Comments